Organic compounds

A method for treating a CXCR2 receptor mediated condition or disease, comprising:

• administering to a subject in need thereof an effective amount of at least one compound represented by formula I
• or a solvate, a hydrate or a pharmaceutically acceptable salt thereof, wherein
• R1 is H, a 3 to 10 membered carbocyclic group optionally substituted by one or more Z groups, a 3 to 10 membered heterocyclic group optionally substituted by one or more Z groups, (C1-C4 alkyl)- 3 to 10 membered carbocyclic group optionally substituted by one or more Z groups, (C1-C4 alkyl)- 3 to 10 membered heterocyclic group optionally substituted by one or more Z groups, C1-C6 alkyl optionally substituted by one or more halogen atoms, CN or OH groups, C1-C6 alkoxy optionally substituted by one or more halogen atoms or OH groups, or an ether group containing 2 to 10 carbon atoms and 1 to 3 oxygen atoms, wherein the ether group is optionally substituted by one or more substituents each independently selected from OH, halogen, a 3 to 10 membered carbocyclic group optionally substituted by one or more Z groups and a 3 to 10 membered heterocyclic group optionally substituted by one or more Z groups;
• R2 is a 3 to 10 membered carbocyclic group optionally substituted by one or more Z groups, a 3 to 10 membered heterocyclic group optionally substituted by one or more Z groups, (C1-C4alkyl)- 3 to 10 membered carbocyclic group optionally substituted by one or more Z groups, (C1-C4 alkyl)- 3 to 10 membered heterocyclic group optionally substituted by one or more Z groups, C1-C6 alkyl optionally substituted by one or more halogen atoms, CN or OH groups, C1-C6 alkoxy optionally substituted by one or more halogen atoms or OH groups, or an ether group containing 2 to 10 carbon atoms and 1 to 3 oxygen atoms, wherein the ether group is optionally substituted by one or more substituents each independently selected from OH, halogen, a 3 to 10 membered carbocyclic group optionally substituted by one or more Z groups and a 3 to 10 membered heterocyclic group optionally substituted by one or more Z groups;
• or
• R1 and R2 together with the carbon atom to which they are attached form 3 to 10 membered carbocyclic group optionally substituted by one or more Z groups, or a 3 to 10 membered heterocyclic group optionally substituted by one or more Z groups;
• R3 is hydrogen, halogen or cyano;
• R4 is H, C1-C8 alkyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl or (C1-C4 alkyl)-R6, wherein the alkyl groups are each optionally substituted by one or more halogen atoms;
• R5 is C1-C8 alkyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, (C1-C4 alkyl)-C3-C8 cycloalkyl or (C1-C4 alkyl)-C5-C8 cycloalkenyl, wherein the alkyl groups are each optionally substituted by one or more halogen atoms;
• or
• R4 and R5, together with the nitrogen and oxygen atoms to which they are attached, form a 5 to 10 membered heterocyclic group optionally substituted by one or more Z groups;
• R6 is selected from a 3 to 10 membered carbocyclic group optionally substituted by one or more Z groups, a 3 to 10 membered heterocyclic group optionally substituted by one or more Z groups, NR7R9, NR7(SO2)R9, (SO2)NR7R9, (SO2)R9, NR7C(O )R9, C(O)NR7R9, NR7C(O)NR8R9, NR7C(O)OR9, C(O)OR7, OC(O)R9, OC(O)NR7, C(O)R9, SR7, CN and NO2;
• R7 and R8 are each independently selected from H, C1-C6 alkyl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl and —(C1-C3 alkylene)-C3-C10 cycloalkyl;
• R9 is selected from H, C1-C6 alkyl, —(C1-C3 alkylene)-C3-C10 cycloalkyl, a 3 to 10 membered carbocyclic group and a 3 to 10 membered heterocyclic group, wherein each of the alkyl groups and ring systems is optionally substituted by OH, halo, C1-C3 alkyl and C1-C3 alkoxy;
• X is CR14 or N;
• Z is independently selected from OH;
• a 3 to 10 membered carbocyclic group;
• a 3 to 10 membered heterocyclic group;
• benzyl;
• C1-C6 alkyl optionally substituted by one or more halogen atoms, CN or OH groups;
• C1-C6 alkoxy optionally substituted by one or more halogen atoms, CN or OH groups;
• -Oaryl;
• -Obenzyl;
• —O(CH2)2C(O)E;
• NR10(SO2)R12;
• (SO2)NR10R11;
• (SO2)R12;
• NR10C(O)R12;
• C(O)NR10R12;
• NR10C(O)NR11R12;
• NR10C(O)OR12;
• NR10R12;
• C(O)OR10;
• OC(O)R12;
• OC(O)NR10;
• C(O)R12;
• SR12 ;
• CN;
• NO2;
• and halogen;
• or
• where there are two or more Z substitutents, two Z substituents together with the atoms to which they are attached optionally form a 5- to 7-membered carbocyclic or a 4- to 7-membered heterocyclic substituent fused to the ring system;
• a is 0, 1, 2, 3 or 4, wherein the alkylene group is optionally substituted by OH or NH2 when a is 1, 2, 3 or 4;
• E is NR10R12 or OR12;
• each R10 and R11 are independently selected from H, C1-C6 alkyl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl and —(C1-C3 alkylene)-C3-C10 cycloalkyl;
• each R12 is selected from H, C1-C6 alkyl, -(C1-C3 alkylene)-C3-C10 cycloalkyl, a 3 to 10 membered carbocyclic group and a 3 to 10 membered heterocyclic group, wherein each of the ring systems is optionally substituted by OH, halo, C1-C3 alkyl and C1-C3 alkoxy;
• and
• R14 is H or C1-C6 alkyl.